Cargando…

Alchemix, p53 and topoisomerase

Detalles Bibliográficos
Autores principales:	Grand, Roger J, Stewart, Grant S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600614/ https://www.ncbi.nlm.nih.gov/pubmed/26388618

Ejemplares similares

Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
por: McDonald, A. C., et al.
Publicado: (1998)

Targeting DNA topoisomerases: past & future
por: Gmeiner, William H., et al.
Publicado: (2021)

Δ113p53/Δ133p53: survival and integrity
por: Chen, Jun, et al.
Publicado: (2015)

p53 Signaling in Cancers
por: Issaeva, Natalia
Publicado: (2019)

Recent Advances in p53
por: D’Orazi, Gabriella
Publicado: (2021)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

p53 and aging: role of p66Shc
por: Migliaccio, Enrica, et al.
Publicado: (2013)

p53-induced autophagy and senescence
por: Sui, Xinbing, et al.
Publicado: (2015)

Regulation of p53 by Helicobacter pylori
por: Zaika, Alexander, et al.
Publicado: (2012)

Simplify p53: just an activator
por: Engeland, Kurt
Publicado: (2014)

Chromatin dysregulation by mutant p53
por: Pfister, Neil T., et al.
Publicado: (2016)

The Role of p53 Family in Cancer
por: Zawacka-Pankau, Joanna E.
Publicado: (2022)

p53: Pro-aging or pro-longevity?
por: de Keizer*, Peter L.J., et al.
Publicado: (2010)

No Time to Relax and Unwind: Exploration of Topoisomerases and a Growing Field of Study
por: Deweese, Joseph E., et al.
Publicado: (2023)

Topoisomerase 2B Decrease Results in Diastolic Dysfunction via p53 and Akt: A Novel Pathway
por: Moudgil, Rohit, et al.
Publicado: (2020)

High-SETD8 inactivates p53 in neuroblastoma
por: Veschi, Veronica, et al.
Publicado: (2017)

Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins
por: Pommier, Yves, et al.
Publicado: (2018)

p53 further extends its reach
por: Zirngibl, Katharina, et al.
Publicado: (2013)

p53 as a target in myeloproliferative neoplasms
por: Lu, Min, et al.
Publicado: (2012)

Targeting mutant p53 for cancer therapy
por: Oren, Moshe, et al.
Publicado: (2016)

P53 in lung vascular barrier dysfunction
por: Barabutis, Nektarios
Publicado: (2020)

Understanding and Therapeutic Targeting of the p53 Network
por: Bacher, Susanne, et al.
Publicado: (2023)

Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53
por: Baumann, Cindy, et al.
Publicado: (2006)

Losing p53 loosens up ER-stress
por: Byun, Sanguine, et al.
Publicado: (2015)

Mutant p53 and sIL-1Ra
por: Bossi, Gianluca
Publicado: (2015)

Fortifying p53 – beyond Mdm2 inhibitors
por: Sriraman, Anusha, et al.
Publicado: (2016)

The tango of ROS and p53 in tissue stem cells
por: Chen, Youguo, et al.
Publicado: (2018)

Emerging Non-Canonical Functions and Regulation of p53
por: Ranjan, Atul, et al.
Publicado: (2018)

The puzzling interplay between p53 and Sp1
por: Oppenheim, Ariella, et al.
Publicado: (2017)

p53: updates on mechanisms, biology and therapy (II)
por: Lane, David P, et al.
Publicado: (2019)

p53: updates on mechanisms, biology and therapy (I)
por: Lane, David P, et al.
Publicado: (2019)

Legends of p53: untold four-decade stories
por: Lu, Hua
Publicado: (2019)

p53 Function and Dysfunction in Human Health and Diseases
por: D’Orazi, Gabriella
Publicado: (2023)

P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas
por: Sundov, Dinka, et al.
Publicado: (2013)

Nucleolar Stress Response via Ribosomal Protein L11 Regulates Topoisomerase Inhibitor Sensitivity of P53-Intact Cancers
por: Ishihara, Yuka, et al.
Publicado: (2022)

Flipping the “switch” on mutant p53 by zinc metallochaperones: how a brief pulse of zinc can reactivate mutant p53 to kill cancer
por: Yu, Xin, et al.
Publicado: (2019)

Topo2008: DNA Topoisomerases in Biology and Medicine
por: Maxwell, Tony, et al.
Publicado: (2009)

New potential instrument to fight hepatocellular cancer by restoring p53
por: Vincent, Franklin C., et al.
Publicado: (2011)

The SLC25A1-p53 mutant crosstalk
por: Albanese, Chris, et al.
Publicado: (2015)

Genome-protective topoisomerase 2a-dependent G2 arrest requires p53 in hTERT-positive cancer cells
por: Lockwood, Nicola, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dloegb56175dsm7i0cdiurpfeq